First Wave BioPharma up on application for human study of pancreatic disorder drug

GridAI Technologies

30/11/2022 13:18

** Shares of First Wave BioPharma Inc  FWBI.O  up 4.3% at 
$0.82 premarket
    ** Company submits application to U.S. FDA requesting
authorization for human clinical trials for a new formulation of
its experimental drug adrulipase 
    ** Drug being studied as a potential treatment for a type of
pancreatic disorder associated with cystic fibrosis and chronic
pancreatitis 
    ** Company says it expects to start a mid-stage study of the
formulation in early 2023, if the FDA grants authorization for
the trial in the next 30 days
    ** Anticipate topline data from the study towards the end of
H1 of 2023 - FWBI 
    ** As of last close, company's shares down ~98% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com))